Default company panoramic image


Oroxcell is a drug discovery and development company identifying new generation of chemical entities dedicated to pain treatment.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Romainville, IDF, France
  • Currency EUR
  • Founded July 2004
  • Employees 25
  • Website

Company Summary

Primary clinical indications of Oroxcell compounds are visceral, chronic, neuropathic and osteoarthritic pain. ORC056, lead candidate, shows an excellent safety profile and a strong analgesic effect in all animal models tested. The compounds benefit from a strong IP and have low cost of synthesis (5 chemical steps). Oroxcell is looking for 1.5 M€ to pursue preclinical development of ORC056 up to an indentified deal with a major Pharma leader.


  • Default avatar
    Jean Pachot
    President and CSO

    - 24 years experience in Pharma industry in various managing positions,
    - Responsible for the creation of the Investigation of Drug Transport unit,
    - Participation in the research and development of Ketek®, Rulid®, Mifegyne ®, Odrik® HMR1297, HMR1404, HMR3270, HMR3432 and contribution to more than 18 R&D programs.

  • Default avatar
    Christophe Dini

    - 20 years experience in Pharma industry as Group Leader in Medicinal Chemistry, Project Leader in preclinical development…,
    - Responsible for several research programs, in nutrition, oncology and infectious diseases, and recognized as expert in the field of antibacterial research,
    - Author of several publications, patents, reviews and book chapters.